PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

This study is a multicenter, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of prothrombin complex concentrate (PCC) in the treatment of bleeding episodes in patients with hemophilia A with inhibitors. All participants received on-demand PCC therapy during bleeding episodes, with dosing adjusted by investigators according to the type of bleeding. The recommended dose was 50 IU/kg per infusion, administered every 8-12 hours, with a maximum total daily dose not exceeding 150 IU/kg. If no effective hemostasis was achieved within 24 hours, investigators could decide to add other hemostatic agents or switch to alternative treatments.

NCT Number	NCT07406139
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: North China University of Science and Technology, The Second Affiliated Hospital of Kunming Medical University, The Second People's Hospital of Anhui Province, Children's Hospital of Chongqing Medical University, Union Hospital, Affiliated to Fujian Medical University, The First Affiliated Hospital of Xiamen University, First Affiliated Hospital of Guangxi Medical University
Conditions	Hemophilia, Inhibitors
Enrollment	30 participants
Start Date	2026-03-01
Primary Completion	2026-12-20 (estimated)
Study Completion	2026-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-02-12